

## 해외 바이오의약품 임상 현황 (2020.06.08~2020.06.14)

한국바이오의약품협회, 2020.6.16.  
출처: ClinicalTrials.gov

### ○ 미국 10건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04408599	A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors Ovarian Cancer Gastric Cancer Colo-rectal Cancer	Drug: NC410	NextCure, Inc.	Phase 1 Phase 2
NCT04287868	Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies	Cervical Cancer HPV Cancers Anal Cancer Oropharyngeal Cancer Vulvar, Vaginal, Penile, Rectal Cancer	Biological: PDS0101 Biological: M7824 Biological: NHS-IL12	National Cancer Institute (NCI) National Institutes of Health Clinical Center (CC)	Phase 1 Phase 2
NCT04247282	Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for p16-Negative Resectable Head and Neck Squamous Cell Carcinoma	Head and Neck Cancer Head and Neck Neoplasms	Drug: M7824 Drug: N803 Biological: TriAd vaccine	National Cancer Institute (NCI) National Institutes of Health Clinical Center (CC)	Phase 1 Phase 2
NCT04421404	Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients	COVID-19 Sars-CoV2	Biological: COVID-19 Convalescent Plasma (CCP) Biological: Placebo	Priscilla Hsue, MD Blood Systems Research Institute San Francisco General Hospital University of California, San Francisco	Phase 2
NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma	Aggressive Non-Hodgkin Lymphoma ALK-Positive Large B-Cell Lymphoma B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma Diffuse Large B-Cell Lymphoma, Not Otherwise Specified EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements High Grade B-Cell Lymphoma, Not Otherwise Specified Primary Mediastinal (Thymic) Large B-Cell Lymphoma T-Cell/Histiocyte-Rich Large B-Cell Lymphoma	Drug: Polatuzumab Vedotin Biological: Rituximab Drug: Prednisone Drug: Etoposide Drug: Doxorubicin Drug: Cyclophosphamide Biological: Filgrastim	University of Washington National Cancer Institute (NCI) Genentech, Inc.	Phase 1
NCT04099836	Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib	Non Small Cell Lung Cancer	Drug: Atezolizumab Drug: Bevacizumab	Duke University	Phase 2
NCT04061980	Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer	BRAF NP_004324.2:p.V600M BRAF V600E Mutation Present Metastatic Thyroid Gland Carcinoma Refractory Thyroid Gland Carcinoma Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8 Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8 Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8	Drug: Binimetinib Drug: Encorafenib Biological: Nivolumab	Providence Health & Services	Phase 2
NCT04412057	Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury	COVID-19 Pneumonia Acute Lung Injury ARDS	Drug: CERC-002 Drug: Placebo	Aevi Genomic Medicine, LLC, a Cerecor company Cerecor Inc	Phase 2
NCT04427501	A Study of LY3819253 (LY-CoV555) in Participants With Early Mild to Moderate COVID-19 Illness	COVID-19	Drug: LY3819253 Drug: Placebo	Eli Lilly and Company AbCellera Biologics Inc.	Phase 2
NCT04394650	A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma	Multiple Myeloma	Biological: CC-98633	Juno Therapeutics, a Subsidiary of Celgene	Phase 1

### ○ 중국 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04425187	Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC	PFS	Drug: Gefitinib Drug: Bevacizumab Combined With Gefitinib	Fudan University	Phase 2
NCT04361812	Comparison of Pharmacokinetics and Safety of Recombinant Anti IgE Humanized Monoclonal Antibody for Injection(HS632) and Omalizumab With a Single Injection (Xolair®)	Similarity of Pharmacokinetics and Safety	Drug: HS632 Drug: Omalizumab (Xolair®)	Zhe Jiang Hisun Bioray Bio-pharmaceutical Co.Ltd	Phase 1

### ○ 일본 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04397263	A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease	Crohn's Disease	Drug: Guselkumab	Janssen Pharmaceutical K.K.	Phase 3